Regulatory Catalyst, Generic Drug Index Updates: $IPCI

publication date: Mar 12, 2010
 | 
author/source: Mike Havrilla
Download Print Send a summary of this page to someone via email.
Previous | Next
 

Shares of Intellipharmaceutics (NASDAQ: IPCI) surged 172% today following a patent litigation settlement announcement after the market close on Thursday for a generic formulation of Focalin XR that is licensed to Par Pharma (NYSE: PRX). $IPCI is a component in both the HavRx Generic Drug and Regulatory Catalyst indexes and is awaiting a FDA decision along with $PRX for a pending ANDA for Dexmethylphenidate XR as a generic formulation of the ADHD drug Focalin XR.

mikehavRx.com Index Updates is a premium service that provides investors with time-saving information and updates on unique global baskets of stocks that are organized and managed within the 18 HavRx Stock Indexes outlined below that are being tracked at the Investars YOU website since June 2009. Please visit www.mikehavRx.com for more details on my new publishing company, website, and premium service.

Disclosure: No positions

 

0 Comments Posted Leave a comment

 

Add a comment:

Sign in to comment on this entry. (Required)


www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and binary event tracking for FDA decisions and clinical trials, including 600+ events and 400+ companies with approximately 200 stocks trading under $5 per share and 80+ private companies. The home page includes an overview of the binary event tracking service and the secure checkout page includes currently offered discount promo codes at https://mikehavrx.ssl.subhub.com/subscribe

 
Previous | Next